Milica R Popovic

Dr. Milica R Popovic


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DSDaniela Benedeto Stojanov
Daniela Benedeto Stojanov
VNVanja P. Ničković
Vanja P. Ničković
GPGordana Petrović
Gordana Petrović
ARAndrija Rančić
Andrija Rančić
IGIvan Grgov
Ivan Grgov
DSDušan Sokolović
Dušan Sokolović
Melatonin (MLT), earlier described as an effective anti-inflammatory agent, could be a beneficial adjunctive drug for sepsis treatment. This study aimed to determine the effects of MLT application in lipopolysaccharide (LPS)-induced sepsis in Wistar rats by determining the levels of liver tissue pro-inflammatory cytokines (TNF-α, IL-6) and NF-κB as well as hematological parameters indicating the state of sepsis. Additionally, an immunohistological analysis of CD14 molecule expression was conducted. Our research demonstrated that treatment with MLT prevented an LPS-induced increase in pro-inflammatory cytokines TNF-α and IL-6 and NF-κB levels, and in the neutrophil to lymphocyte ratio (NLR). On the other hand, MLT prevented a decrease in the blood lymphocyte number induced by LPS administration. Also, treatment with MLT decreased the liver tissue expression of the CD14 molecule observed after sepsis induction. In summary, in rats with LPS-induced sepsis, MLT was shown to be a significant anti-inflammatory agent with the potential to change the liver’s immunological marker expression, thus ameliorating liver function.

12 June 2025 in Hematology Reports
Verified
Journal Article
Open access
PDF file
Edin KarisikEdin Karisik
Edin Karisik
ZSZorica Stanojević-Ristić
Zorica Stanojević-Ristić
MJMarija Jevtic
Marija Jevtic
JRJulijana Vlastimir Rašić
Julijana Vlastimir Rašić
MMMiljana Maric
Miljana Maric
MPMilica R Popovic
Milica R Popovic
Background: Cephalosporins are considered safe antibiotics. However, serious hematological abnormalities may occur, although rarely, after their therapeutic use. Case Presentation: We present a case of pancytopenia in a 72-year-old female patient treated with ceftriaxone for a urinary tract infection. After five days of therapy, pancytopenia was observed. Other causes were excluded through extensive diagnostic evaluation, including immunological tests, viral serologies, bone marrow aspiration, and peripheral blood smear. The patient’s clinical condition significantly improved following the discontinuation of ceftriaxone and the administration of granulocyte colony-stimulating factor (G-CSF). Bone marrow findings revealed hypocellularity without malignant infiltration, and peripheral smear showed no dysplasia, blasts, or hemolysis. Conclusions: This case demonstrates that ceftriaxone, although widely regarded as a safe antibiotic, can induce rare but serious hematologic complications such as pancytopenia. A high index of suspicion is required when patients on antibiotic therapy develop unexplained cytopenias. Detailed medication history, exclusion of other causes, and prompt discontinuation of the suspected drug are essential. The patient’s favorable outcome supports the likelihood of an idiosyncratic, immune-mediated mechanism. Future research should explore pharmacogenomic screening in patients at increased risk, particularly involving HLA variants.

15 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Edin KarisikEdin Karisik
Edin Karisik
ZSZorica Stanojević-Ristić
Zorica Stanojević-Ristić
MJMarija Jevtic
Marija Jevtic
JRJulijana Vlastimir Rašić
Julijana Vlastimir Rašić
MMMiljana Maric
Miljana Maric
MPMilica R Popovic
Milica R Popovic
Cephalosporins are considered safe antibiotics. However, serious hematological abnormalities may occur, although rarely, after their therapeutic use. We present a case of pancytopenia in a patient treated with ceftriaxone, where, after ruling out other potential causes through extensive diagnostic evaluation, an idiosyncratic drug reaction was established. The patient's clinical condition significantly improved following the discontinuation of ceftriaxone and the administration of filgrastim. This case highlights the importance of recognizing the potential for rare but serious hematologic adverse effects associated with commonly used antibiotics such as ceftriaxone. Early identification and prompt management of these adverse effects are critical to ensure optimal patient outcomes and prevent serious complications.